Total
0
Shares
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Medibio has completed the first of four planned ilumen pilot programs with Compass Group
  • ilumen is a program that provides data-driven feedback to help employees improve their mental well-being
  • ilumen was offered voluntarily to participants within the Business and Industry Division in the U.K.
  • The program achieved a voluntary engagement rate of 65.3 per cent
  • Medibio’s shares are up 9.09 per cent, with shares trading at 1.2 cents a share

Medibio has completed the first of four planned ilumen pilot programs with Compass Group.

As part of the Health and Wellbeing element of its global purpose strategy, Compass Group implements various programs to support and improve the overall mental well-being and physical health of its employees and the employees of its clients.

ilumen is a program that provides data-driven feedback to help employees improve their mental well-being.

Medibio believes when employees are given the right tools and make the effort to take the appropriate measures towards their mental well-being, they perform better in the workplace.

Under the terms of the contract, ilumen was offered voluntarily to participants within the Business and Industry Division in the United Kingdom.

Medibio has reported participants had access to the ilumen program over a four-week period which commenced in mid-August. The program achieved a voluntary engagement rate of 65.3 per cent.

“We are especially pleased with the engagement rate achieved in this initial program with Compass Group and look forward to delivering strong results moving forward,” Medibio’s Senior VP of Corporate Health Jennifer Solitario said.

The results from the first pilot program have been presented to Compass and have offered insights to better support and manage the well-being of its workforce.

Medibio is continuing to work with Compass Group with two additional pilot programs. One will begin shortly and the fourth pilot will commence in January.

Medibio’s shares are up 9.09 per cent, with shares trading at 1.2 cents apiece as at 3:20 pm AEDT.

MEB by the numbers
More From The Market Herald
Dimerix (ASX:DXB) - Managing Director and CEO, Nina Webster

" Dimerix (ASX:DXB) expands DMX-200 study into Australia

Dimerix (DXB) has entered an agreement with the NHMRC Clinical Trials Centre at the University of Sydney to expand the CLARITY 2.

" ACCC scrambles to halt Virtus Health’s (ASX:VRT) purchase of Healius (ASX:HLS) IVF clinics

The ACCC has taken “a significant step” as it seeks an urgent injunction to stop Virtus Health’s (VRT) proposed acquisition of Adora Fertility
IDT Australia (ASX:IDT) - Chair, Alan Fisher

" IDT Australia (ASX:IDT) signs manufacturing deal with Monash University

IDT Australia (IDT) has entered a master services agreement and services order with Monash University.
Prescient Therapeutics (PTX) - CEO and MD, Steven Yatomi Clarke

" Prescient Therapeutics (ASX:PTX) to present new OmniCAR data at conference

Prescient Therapeutics (PTX) will present new results for its OmniCAR drug at the Cell & Gene Meeting on Mesa in California.